FY2027 Earnings Estimate for ASMB Issued By HC Wainwright

Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) - Equities research analysts at HC Wainwright lowered their FY2027 earnings per share (EPS) estimates for Assembly Biosciences in a research note issued to investors on Thursday, November 13th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will post earnings of $1.44 per share for the year, down from their prior forecast of $1.67. HC Wainwright has a "Buy" rating and a $50.00 price target on the stock. The consensus estimate for Assembly Biosciences' current full-year earnings is ($6.87) per share. HC Wainwright also issued estimates for Assembly Biosciences' FY2029 earnings at $3.09 EPS.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.22). Assembly Biosciences had a negative net margin of 117.20% and a negative return on equity of 149.01%. The business had revenue of $10.79 million for the quarter, compared to the consensus estimate of $7.46 million.

ASMB has been the subject of a number of other research reports. Guggenheim increased their price objective on Assembly Biosciences from $31.00 to $39.00 and gave the company a "buy" rating in a research report on Monday, September 8th. Citizens Jmp assumed coverage on Assembly Biosciences in a research report on Wednesday, September 24th. They issued an "outperform" rating and a $38.00 price target for the company. Zacks Research raised Assembly Biosciences to a "hold" rating in a research note on Tuesday, August 19th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Assembly Biosciences in a research note on Wednesday, October 8th. Finally, JMP Securities assumed coverage on shares of Assembly Biosciences in a report on Wednesday, September 24th. They issued a "market outperform" rating and a $38.00 target price for the company. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Assembly Biosciences currently has a consensus rating of "Moderate Buy" and an average target price of $41.25.

Get Our Latest Research Report on ASMB

Assembly Biosciences Stock Performance

Shares of NASDAQ:ASMB opened at $36.71 on Monday. The stock has a market capitalization of $281.64 million, a price-to-earnings ratio of -6.58 and a beta of 0.60. Assembly Biosciences has a 1-year low of $7.75 and a 1-year high of $37.71. The company has a 50 day moving average price of $27.37 and a 200 day moving average price of $21.55.

Hedge Funds Weigh In On Assembly Biosciences

Several institutional investors have recently bought and sold shares of the stock. American Century Companies Inc. bought a new stake in shares of Assembly Biosciences during the 1st quarter worth about $113,000. Acadian Asset Management LLC lifted its stake in shares of Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company's stock worth $219,000 after buying an additional 6,823 shares during the last quarter. Palumbo Wealth Management LLC boosted its holdings in shares of Assembly Biosciences by 3.8% during the 2nd quarter. Palumbo Wealth Management LLC now owns 18,667 shares of the biopharmaceutical company's stock worth $338,000 after buying an additional 681 shares during the period. Geode Capital Management LLC grew its stake in Assembly Biosciences by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company's stock valued at $925,000 after buying an additional 3,312 shares during the last quarter. Finally, Ellsworth Advisors LLC acquired a new position in Assembly Biosciences during the 3rd quarter worth $852,000. 19.92% of the stock is currently owned by institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.

Featured Articles

• Five stocks we like better than Assembly Biosciences
• Investing in the High PE Growth Stocks
• 4 Cold-Weather Stocks to Buy as Winter Spending Heats Up
• Energy and Oil Stocks Explained
• Disney Stock Drops—Will Earnings Pave Way for a YouTube TV Truce?
• 2 Fintech Stocks to Buy Now and 1 to Avoid
• Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Assembly Biosciences Right Now?

Before you consider Assembly Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assembly Biosciences wasn't on the list.

While Assembly Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here